
  
    
      
        Background_NNP
        Stroke_NNP is_VBZ the_DT third_JJ leading_VBG cause_NN of_IN death_NN in_IN adults_NNS ._.
        The_DT 2_CD basic_JJ types_NNS of_IN stroke_NN are_VBP ischemic_JJ stroke_NN and_CC
        hemorrhagic_JJ stroke_NN ._. In_IN ischemic_JJ stroke_NN ,_, the_DT most_RBS common_JJ
        type_NN ,_, a_DT profound_JJ disturbance_NN of_IN focal_JJ cerebral_JJ blood_NN flow_NN
        leads_VBZ to_TO irreversible_JJ parenchymal_NN injury_NN ._. The_DT Siblings_NNP With_IN
        Ischemic_NNP Stroke_NNP Study_NNP (_( SWISS_NNP )_) is_VBZ a_DT multicenter_NN affected_VBD
        sibling_VBG pair_NN study_NN with_IN the_DT aim_NN of_IN identifying_VBG chromosomal_NN
        regions_NNS linked_VBN to_TO ischemic_JJ stroke_NN by_IN using_VBG genome-wide_JJ
        scanning_VBG ._. Family_NN history_NN and_CC twins_NNS studies_NNS support_VBP the_DT
        existence_NN of_IN genetic_JJ susceptibility_NN to_TO stroke_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._.
        Mendelian_NNP disorders_NNS known_VBN to_TO be_VB associated_VBN with_IN an_DT
        increased_VBN risk_NN of_IN stroke_NN include_VBP hemoglobinopathies_NNS ,_,
        dyslipoproteinemias_NNS ,_, and_CC cardioembolic_JJ disorders_NNS [_NN 5_CD ]_NN ._.
        Most_RBS known_VBN Mendelian_NNP stroke_NN disorders_NNS present_JJ in_IN infancy_NN ,_,
        childhood_NN ,_, or_CC young_JJ adulthood_NN and_CC collectively_RB represent_VB
        only_RB a_DT small_JJ proportion_NN of_IN all_DT stroke_NN cases_NNS ._. Several_JJ of_IN
        these_DT Mendelian_NNP disorders_NNS were_VBD recognized_VBN as_IN unique_JJ genetic_JJ
        diseases_NNS because_IN of_IN striking_JJ phenotypic_JJ features_NNS ,_, such_JJ as_IN
        corneal_JJ opacities_NNS and_CC angiokeratomas_NNS of_IN the_DT skin_NN in_IN Fabry_NNP
        disease_NN ._.
        Defining_VBG the_DT genetic_JJ basis_NN for_IN stroke_NN syndromes_NNS that_WDT
        lack_NN striking_JJ phenotypic_JJ features_NNS is_VBZ a_DT more_RBR difficult_JJ task_NN ._.
        Model-dependent_NNP linkage_NN analysis_NN has_VBZ been_VBN used_VBN in_IN large_JJ
        pedigrees_NNS with_IN diseases_NNS such_JJ as_IN cerebral_JJ autosomal_NN dominant_JJ
        arteriopathy_NN with_IN subcortical_JJ infarcts_NNS and_CC
        leukoencephalopathy_NN (_( CADASIL_NNP )_) [_NN 6_CD 7_CD 8_CD 9_CD ]_NN ._. However_RB ,_,
        traditional_JJ linkage_NN analysis_NN is_VBZ unlikely_JJ to_TO be_VB the_DT most_JJS
        expedient_NN method_NN of_IN finding_VBG novel_NN stroke-susceptibility_JJ
        genes_NNS when_WRB carrier_NN status_NN cannot_NN be_VB defined_VBN on_IN the_DT basis_NN of_IN
        distinctive_JJ clinical_JJ ,_, radiographic_JJ ,_, or_CC laboratory_NN
        features_NNS ._.
        One_CD popular_JJ method_NN of_IN identifying_VBG genetic_JJ risk_NN factors_NNS
        has_VBZ been_VBN the_DT candidate_NN gene_NN association_NN study_NN ,_, in_IN which_WDT
        investigators_NNS compare_VBP rates_NNS of_IN one_CD or_CC more_JJR variant_NN
        polymorphisms_NNS of_IN a_DT candidate_NN gene_NN among_IN stroke_NN cases_NNS and_CC
        stroke-free_JJ controls_NNS ._. Identifying_NNP risk_NN factors_NNS depends_VBZ on_IN
        selecting_VBG the_DT right_JJ candidate_NN genes_NNS ,_, a_DT daunting_JJ task_NN
        because_IN the_DT human_JJ genome_NN harbors_NNS about_IN 30_CD ,_, 000_CD genes_NNS ._. A_DT
        candidate_NN gene_NN is_VBZ usually_RB selected_VBN because_IN the_DT gene_NN product_NN
        might_MD relate_VB to_TO pathogenesis_NNS of_IN disease_NN ._.
        Numerous_JJ studies_NNS have_VBP used_VBN a_DT candidate_NN gene_NN approach_NN to_TO
        define_VB genetic_JJ risk_NN factors_NNS for_IN stroke_NN ,_, but_CC so_RB far_RB results_VBZ
        for_IN several_JJ categories_NNS of_IN candidate_NN genes_NNS have_VBP been_VBN
        negative_JJ or_CC conflicting_JJ ._. For_IN example_NN ,_, because_IN about_IN 80_CD %_NN of_IN
        strokes_NNS are_VBP caused_VBN by_IN thrombotic_JJ occlusion_NN of_IN a_DT blood_NN
        vessel_NN ,_, genes_NNS related_VBN to_TO the_DT coagulation_NN system_NN would_MD seem_VB
        logical_JJ candidates_NNS for_IN susceptibility_NN to_TO stroke_NN ._. However_RB ,_,
        despite_IN association_NN of_IN the_DT factor_NN V_NNP G_NNP 1691_CD A_DT (_( factor_NN V_NNP
        Leiden_NNP )_) and_CC prothrombin_NN (_( factor_NN II_NNP )_) G_NNP 20210_CD A_DT mutations_NNS with_IN
        venous_JJ thromboembolism_NN and_CC myocardial_NN infarction_NN [_NN 10_CD 11_CD ]_NN
        ,_, neither_DT mutation_NN is_VBZ strongly_RB associated_VBN with_IN risk_NN of_IN
        stroke_NN [_NN 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._. Although_IN a_DT study_NN of_IN
        British_JJ adults_NNS found_VBD elevated_VBD levels_NNS of_IN serum_NN homocysteine_NN
        to_TO be_VB associated_VBN with_IN an_DT increased_VBN risk_NN of_IN stroke_NN [_NN 19_CD ]_NN ,_,
        a_DT case-control_JJ study_NN of_IN a_DT common_JJ polymorphism_NN
        (_( methylenetetrahydrofolate_NN reductase_NN [_NN MTHFR_NNP ]_NN T_NN 677_CD C_NNP )_) that_IN
        results_NNS in_IN increased_VBN serum_NN homocysteine_NN concentrations_NNS
        found_VBD no_DT difference_NN between_IN patients_NNS with_IN stroke_NN and_CC
        controls_NNS in_IN either_DT genotype_NN or_CC allele_NN frequency_NN [_NN 20_CD ]_NN ._.
        Because_IN antiplatelet_NN agents_NNS with_IN different_JJ mechanisms_NNS of_IN
        action_NN can_MD bring_VB about_IN significant_JJ reductions_NNS in_IN stroke_NN
        risk_NN ,_, several_JJ platelet_NN receptor_NN genes_NNS have_VBP been_VBN tested_VBN as_IN
        candidate_NN stroke_NN susceptibility_NN genes_NNS [_NN 21_CD 22_CD ]_NN ._. To_TO date_NN ,_,
        however_RB ,_, no_DT compelling_JJ evidence_NN for_IN an_DT association_NN between_IN
        any_DT platelet_NN receptor_NN gene_NN polymorphism_NN and_CC risk_NN of_IN stroke_NN
        has_VBZ been_VBN found_VBN ._.
        Conflicting_NNP results_NNS have_VBP been_VBN reported_VBN from_IN studies_NNS on_IN
        the_DT stroke_NN risk_NN factor_NN status_NN of_IN genes_NNS related_VBN to_TO
        myocardial_NN infarction_NN or_CC arterial_NN disease_NN ,_, such_JJ as_IN specific_JJ
        genotypes_NNS of_IN the_DT genes_NNS for_IN angiotensin_NN 1_CD -_: converting_VBG enzyme_NN
        (_( 
        ACE_NNP )_) [_NN 23_CD 24_CD 25_CD 26_CD ]_NN or_CC
        apolipoprotein_NN [_NN 27_CD 28_CD 29_CD 30_CD 31_CD 32_CD 33_CD 34_CD ]_NN ._. Potential_JJ
        confounding_VBG factors_NNS include_VBP the_DT effects_NNS of_IN comorbidity_NN and_CC
        differential_NN mortality_NN rates_NNS [_NN 34_CD 35_CD ]_NN ._. Although_IN the_DT
        degree_NN of_IN stenosis_NNS of_IN the_DT cervical_JJ internal_JJ carotid_NN
        arteries_NNS in_IN symptomatic_JJ patients_NNS correlates_NNS with_IN risk_NN of_IN
        ipsilateral_NN stroke_NN [_NN 36_CD ]_NN ,_, no_DT clear_JJ conclusions_NNS can_MD be_VB
        drawn_VBN from_IN attempts_NNS to_TO relate_VB carotid_NN artery_NN disease_NN to_TO
        specific_JJ genotypes_NNS (_( for_IN example_NN ,_, of_IN the_DT paraoxonase_NN gene_NN 
        PON_NNP ,_, which_WDT is_VBZ thought_VBN to_TO protect_VB
        low-density_NN lipoprotein_NN against_IN oxidative_JJ modification_NN [_NN 37_CD
        ]_NN ,_, or_CC of_IN the_DT endothelial_NN nitric_JJ oxide_NN synthase_NN gene_NN [_NN 38_CD ]_NN
        )_) ._.
        Thus_RB ,_, results_NNS of_IN the_DT candidate_NN gene_NN approach_NN have_VBP so_RB far_RB
        failed_VBD to_TO define_VB genetic_JJ risk_NN factors_NNS for_IN stroke_NN ._.
        Furthermore_RB ,_, if_IN important_JJ functional_JJ mutations_NNS should_MD arise_VB
        in_IN noncoding_VBG regions_NNS without_IN significant_JJ disequilibrium_NN
        with_IN the_DT site_NN of_IN a_DT screened_VBD polymorphism_NN ,_, the_DT association_NN
        analysis_NN may_MD exclude_VB the_DT true_JJ disease_NN susceptibility_NN
        locus_JJ ._.
        A_DT genome-wide_JJ scanning_VBG approach_NN in_IN sibling_VBG pairs_NNS may_MD
        expedite_VB discovery_NN of_IN novel_NN risk_NN factor_NN genes_NNS ._. The_DT basic_JJ
        goal_NN of_IN the_DT genome-wide_JJ scan_VB with_IN microsatellite_NN markers_NNS is_VBZ
        to_TO identify_VB chromosomal_NN regions_NNS linked_VBN to_TO a_DT disease_NN
        phenotype_NN by_IN determining_VBG whether_IN polymorphisms_NNS in_IN the_DT
        microsatellite_NN markers_NNS segregate_VB with_IN disease_NN within_IN a_DT
        cohort_NN of_IN pedigrees_NNS ._. Microsatellites_NNP are_VBP not_RB functional_JJ ;_:
        they_PRP are_VBP noncoding_VBG regions_NNS of_IN DNA_NNP that_WDT allow_VBP identification_NN
        of_IN chromosomal_NN regions_NNS held_VBN in_IN common_JJ by_IN members_NNS of_IN a_DT
        pedigree_NN ._.
        The_DT collection_NN of_IN sibling_VBG pairs_NNS and_CC analysis_NN of_IN mean_NN
        proportion_NN of_IN alleles_NNS shared_VBN that_WDT are_VBP identical_JJ (_( by_IN descent_NN
        or_CC state_NN )_) by_IN use_NN of_IN a_DT highly_RB polymorphic_JJ panel_NN of_IN genetic_JJ
        markers_NNS has_VBZ come_VBN to_TO be_VB a_DT standard_JJ protocol_NN for_IN detecting_VBG
        linkage_NN of_IN a_DT disease_NN susceptibility_NN locus_JJ to_TO a_DT chromosomal_NN
        region_NN ._. The_DT technique_NN has_VBZ been_VBN applied_VBN to_TO a_DT broad_JJ range_NN of_IN
        other_JJ disorders_NNS ,_, including_VBG multiple_JJ sclerosis_NN [_NN 39_CD 40_CD 41_CD 42_CD
        ]_NN ,_, Alzheimer_NNP disease_NN [_NN 43_CD 44_CD 45_CD ]_NN ,_, type_NN 1_CD diabetes_NN [_NN 46_CD ]_NN
        ,_, type_NN 2_CD diabetes_NN [_NN 47_CD ]_NN ,_, asthma_NN [_NN 48_CD ]_NN ,_, and_CC systemic_JJ
        lupus_JJ erythematosus_JJ [_NN 49_CD ]_NN ._. The_DT use_NN of_IN such_JJ
        linkage-mapping_JJ strategies_NNS offers_VBZ the_DT advantage_NN of_IN
        model-independence_JJ ,_, computational_NN speed_NN ,_, and_CC systematic_JJ
        identification_NN of_IN novel_NN loci_NN [_NN 39_CD ]_NN ._.
        Thus_RB ,_, linkage_NN analysis_NN using_VBG a_DT genome-wide_JJ scan_VB may_MD
        yield_VB positive_JJ results_NNS more_RBR efficiently_RB than_IN testing_VBG
        candidate_NN genes_NNS a_DT few_JJ at_IN a_DT time_NN ._. However_RB ,_, we_PRP do_VBP not_RB
        consider_VB these_DT approaches_NNS to_TO be_VB mutually_RB exclusive_JJ ._.
        Genome-wide_NNP linkage_NN analysis_NN may_MD guide_VB selective_JJ candidate_NN
        gene_NN evaluations_NNS within_IN regions_NNS of_IN importance_NN ._. The_DT goal_NN of_IN
        SWISS_NNP is_VBZ to_TO help_VB to_TO identify_VB the_DT chromosomal_NN regions_NNS that_WDT
        should_MD be_VB searched_VBD for_IN candidate_NN genes_NNS ._.
        The_DT paucity_NN of_IN genome-wide_JJ scanning_VBG studies_NNS in_IN the_DT
        stroke_NN literature_NN to_TO date_NN is_VBZ mainly_RB due_JJ to_TO theoretical_JJ and_CC
        logistical_JJ factors_NNS that_WDT make_VBP such_JJ studies_NNS difficult_JJ to_TO
        design_VB ._. Ischemic_NNP stroke_NN itself_PRP represents_VBZ a_DT heterogeneous_JJ
        phenotype_NN ._. Various_JJ systems_NNS have_VBP been_VBN used_VBN to_TO classify_VB
        subtypes_NNS of_IN ischemic_JJ stroke_NN [_NN 50_CD ]_NN ._. For_IN example_NN ,_, the_DT Trial_NNP
        of_IN ORG_NNP 10172_CD in_IN Acute_NNP Stroke_NNP Treatment_NNP (_( TOAST_NNP )_) investigators_NNS
        classified_VBD stroke_NN into_IN large-artery_JJ atherosclerosis_NNS ,_,
        cardioembolism_NN ,_, small-vessel_JJ occlusion_NN ,_, stroke_NN of_IN other_JJ
        etiology_NN ,_, and_CC stroke_NN of_IN undetermined_JJ etiology_NN [_NN 51_CD ]_NN ._.
        Uncertainty_NN exists_VBZ as_IN to_TO whether_IN the_DT clinical_JJ heterogeneity_NN
        of_IN the_DT ischemic_JJ stroke_NN phenotype_NN relates_VBZ to_TO heterogeneity_NN
        in_IN genetic_JJ risk_NN factors_NNS ._.
        Logistically_NNP ,_, the_DT collection_NN of_IN a_DT large_JJ number_NN of_IN
        sibling_VBG pairs_NNS concordant_NN for_IN stroke_NN is_VBZ a_DT daunting_JJ task_NN ._.
        Stroke_NNP affects_VBZ an_DT elderly_JJ population_NN and_CC carries_VBZ a_DT modest_JJ
        case_NN fatality_NN rate_NN ._. Patients_NNS may_MD be_VB rendered_VBN incompetent_JJ to_TO
        consent_VB to_TO a_DT genetics_NNS study_VBP by_IN the_DT stroke_NN itself_PRP ._. Often_RB ,_,
        members_NNS of_IN a_DT sibship_NN are_NN separated_VBN by_IN large_JJ geographical_JJ
        distances_NNS ._. In_IN a_DT preliminary_JJ study_NN ,_, we_PRP found_VBD that_IN ,_, whereas_IN 1_CD
        in_IN 10_CD patients_NNS with_IN stroke_NN report_NN having_VBG a_DT living_NN affected_VBN
        sibling_VBG ,_, only_RB 1_CD in_IN 50_CD had_VBD an_DT affected_VBN sibling_VBG living_VBG in_IN the_DT
        same_JJ city_NN as_IN the_DT proband_NN [_NN 52_CD ]_NN ._.
        SWISS_NNP is_VBZ designed_VBN to_TO overcome_VB these_DT hurdles_NNS as_RB far_RB as_IN
        possible_JJ ._. The_DT purpose_NN of_IN this_DT paper_NN is_VBZ to_TO describe_VB the_DT
        SWISS_NNP protocol_NN in_IN detail_NN ._.
      
      
        Research_NNP Design_NNP and_CC Methods_NNP
        
          Aim_NNP
          The_DT aim_NN of_IN SWISS_NNP is_VBZ to_TO test_VB the_DT hypothesis_NNS that_IN the_DT
          human_JJ genome_NN contains_VBZ chromosomal_NN regions_NNS associated_VBN with_IN
          ischemic_JJ stroke_NN by_IN means_NNS of_IN genome-wide_JJ scanning_VBG in_IN DNA_NNP
          samples_NNS collected_VBN from_IN 300_CD sibling_VBG pairs_NNS concordant_NN for_IN
          ischemic_JJ stroke_NN and_CC from_IN 200_CD discordant_JJ siblings_NNS ._.
        
        
          Definition_NNP of_IN ischemic_JJ stroke_NN and_CC its_PRP$
          subtypes_NNS
          Stroke_NNP is_VBZ defined_VBN according_VBG to_TO World_NNP Health_NNP
          Organization_NNP criteria_NNS [_NN 53_CD ]_NN as_RB rapidly_RB developing_VBG signs_NNS
          of_IN a_DT focal_JJ or_CC global_JJ disturbance_NN of_IN cerebral_JJ function_NN ,_,
          with_IN symptoms_NNS lasting_JJ 24_CD hours_NNS or_CC longer_RBR or_CC leading_VBG to_TO
          death_NN with_IN no_DT apparent_JJ cause_NN other_JJ than_IN vascular_NN origin_NN ._.
          Patients_NNS are_VBP classified_VBN as_IN having_VBG an_DT ischemic_JJ stroke_NN if_IN
          they_PRP had_VBD computed_JJ tomographic_JJ or_CC magnetic_JJ resonance_NN
          imaging_NN of_IN the_DT brain_NN done_VBN within_IN 7_CD days_NNS of_IN onset_NN of_IN
          symptoms_NNS that_IN either_DT identified_VBD the_DT symptomatic_JJ cerebral_JJ
          infarct_NN or_CC failed_VBD to_TO identify_VB an_DT alternative_NN cause_NN of_IN the_DT
          symptoms_NNS ._. Classification_NNP of_IN strokes_NNS into_IN subtypes_NNS is_VBZ done_VBN
          according_VBG to_TO the_DT validated_JJ TOAST_NNP diagnostic_JJ criteria_NNS [_NN 51_CD
          ]_NN ._. Subtype_NNP diagnosis_NN is_VBZ made_VBN on_IN the_DT basis_NN of_IN available_JJ
          and_CC relevant_JJ information_NN obtained_VBN up_IN to_TO 3_CD months_NNS after_IN
          the_DT stroke_NN ,_, because_IN initial_JJ subtype_NN diagnosis_NN varies_VBZ from_IN
          final_JJ diagnosis_NN in_IN approximately_RB one-third_NN of_IN cases_NNS [_NN 54_CD
          ]_NN ._.
        
        
          Study_NN population_NN
          
            Probands_NNP
            Probands_NNP are_VBP adult_NN men_NNS and_CC women_NNS who_WP 1_LS )_) have_VBP a_DT
            diagnosis_NN of_IN at_IN least_JJS 1_CD ischemic_JJ stroke_NN confirmed_VBN by_IN
            the_DT study_NN neurologist_NN ,_, 2_LS )_) report_NN having_VBG at_IN least_JJS 1_CD
            living_VBG full_JJ sibling_VBG with_IN a_DT history_NN of_IN stroke_NN ,_, and_CC 3_LS )_)
            have_VBP attained_VBN their_PRP$ 18_CD th_NN birthday_NN at_IN the_DT time_NN of_IN
            enrollment_NN in_IN the_DT study_NN ._. If_IN probands_NNS have_VBP had_VBN more_JJR than_IN
            one_CD ischemic_JJ stroke_NN ,_, the_DT most_RBS recent_JJ is_VBZ the_DT proband_NN
            index_NN stroke_NN ._. Probands_NNP are_VBP not_RB excluded_VBN from_IN the_DT study_NN
            for_IN radiographic_JJ evidence_NN of_IN hemorrhagic_JJ transformation_NN
            of_IN an_DT ischemic_JJ stroke_NN ._.
            Probands_NNP are_VBP not_RB enrolled_VBN if_IN any_DT of_IN the_DT following_VBG
            conditions_NNS apply_VBP :_: 1_LS )_) The_DT index_NN stroke_NN is_VBZ presumed_VBN to_TO be_VB
            iatrogenic_JJ -_: that_DT is_VBZ ,_, onset_NN of_IN symptoms_NNS occurred_VBD within_IN
            48_CD hours_NNS after_IN an_DT invasive_JJ cerebrovascular_NN or_CC
            cardiovascular_JJ procedure_NN ,_, such_JJ as_IN coronary_JJ artery_NN
            bypass_NN grafting_VBG ,_, a_DT catheter-based_JJ procedure_NN on_IN carotid_NN
            or_CC coronary_JJ arteries_NNS ,_, carotid_NN endarterectomy_NN ,_, heart_NN
            valve_NN surgery_NN ,_, or_CC thoracic_JJ or_CC thoracoabdominal_NN aortic_JJ
            aneurysm_NN repair_NN ._. 2_LS )_) The_DT index_NN stroke_NN is_VBZ presumed_VBN due_JJ to_TO
            vasospasm_NN after_IN nontraumatic_JJ subarachnoid_NN hemorrhage_NN -_:
            that_DT is_VBZ ,_, the_DT onset_NN of_IN symptoms_NNS occurred_VBD within_IN 60_CD days_NNS
            after_IN the_DT onset_NN of_IN a_DT nontraumatic_JJ subarachnoid_NN
            hemorrhage_NN ._. Virtually_RB all_DT delayed_VBN cerebral_JJ ischemia_NN
            occurs_VBZ 5_CD to_TO 21_CD days_NNS after_IN subarachnoid_NN hemorrhage_NN [_NN 55_CD
            56_CD ]_NN ._. 3_LS )_) The_DT index_NN stroke_NN is_VBZ presumed_VBN due_JJ to_TO an_DT
            autoimmune_JJ condition_NN -_: that_DT is_VBZ ,_, the_DT patient_NN has_VBZ a_DT
            history_NN of_IN brain-biopsy-proven_JJ central_JJ nervous_JJ system_NN
            vasculitis_NNS ._. 4_LS )_) The_DT patient_NN is_VBZ known_VBN to_TO have_VB any_DT of_IN the_DT
            following_VBG single-gene_JJ or_CC mitochondrial_NN disorders_NNS
            recognized_VBN by_IN a_DT distinctive_JJ phenotype_NN :_: CADASIL_NNP ,_, Fabry_NNP
            disease_NN ,_, homocystinuria_NN ,_, mitochondrial_NN encephalopathy_NN
            with_IN lactic_JJ acidosis_NNS and_CC stroke-like_JJ episodes_NNS (_( MELAS_NNP )_) ,_,
            or_CC sickle_NN cell_NN anemia_NN ._. We_PRP excluded_VBD probands_NNS with_IN these_DT
            disorders_NNS because_IN their_PRP$ enrollment_NN might_MD confound_NN the_DT
            genome_NN scan_VB for_IN novel_NN risk_NN factors_NNS ._. 5_LS )_) The_DT patient_NN had_VBD
            a_DT mechanical_JJ aortic_JJ valve_NN or_CC a_DT mechanical_JJ mitral_NN valve_NN
            at_IN the_DT time_NN of_IN index_NN stroke_NN onset_NN ._. We_PRP chose_VBD this_DT
            criterion_NN because_IN of_IN the_DT high_JJ likelihood_NN that_IN ischemic_JJ
            stroke_NN is_VBZ iatrogenic_JJ in_IN such_JJ patients_NNS ._. 6_CD )_) The_DT patient_NN
            had_VBD untreated_JJ or_CC actively_RB treated_VBN bacterial_JJ
            endocarditis_NNS at_IN the_DT time_NN of_IN index_NN stroke_NN onset_NN ._.
          
          
            Concordant_NNP Siblings_NNP
            To_TO be_VB enrolled_VBN as_IN a_DT concordant_NN sibling_VBG ,_, the_DT subject_JJ
            must_MD have_VB a_DT full_JJ sibling_VBG enrolled_VBN as_IN a_DT proband_NN in_IN
            SWISS_NNP ._. Other_JJ eligibility_NN criteria_NNS for_IN concordant_NN
            siblings_NNS are_VBP identical_JJ to_TO those_DT of_IN probands_NNS ._. Both_DT
            proband_NN and_CC concordant_NN sibling_VBG must_MD be_VB at_IN least_JJS 18_CD
            years_NNS old_JJ at_IN the_DT time_NN of_IN enrollment_NN and_CC both_DT must_MD meet_VB
            the_DT same_JJ definition_NN of_IN ischemic_JJ stroke_NN ._. For_IN concordant_NN
            siblings_NNS ,_, the_DT diagnosis_NN of_IN ischemic_JJ stroke_NN is_VBZ verified_VBN
            retrospectively_RB by_IN the_DT Stroke_NNP Verification_NNP Committee_NNP
            (_( SVC_NNP )_) ._. This_DT is_VBZ a_DT central_JJ ,_, genotype-blinded_JJ committee_NN of_IN
            study-appointed_JJ neurologists_NNS (_( Appendix_NNP )_) ,_, which_WDT
            adjudicates_NNS the_DT diagnosis_NN and_CC subtype_NN of_IN ischemic_JJ
            stroke_NN for_IN concordant_NN siblings_NNS ,_, using_VBG standardized_JJ ,_,
            prespecified_JJ criteria_NNS ._. Although_IN the_DT subtype_NN of_IN the_DT
            sibling_VBG 's_POS index_NN ischemic_JJ stroke_NN is_VBZ determined_VBN ,_,
            enrollment_NN is_VBZ not_RB restricted_VBN to_TO siblings_NNS with_IN the_DT same_JJ
            ischemic_JJ stroke_NN subtype_NN as_IN probands_NNS ._.
          
          
            Discordant_NNP Siblings_NNP
            Inclusion_NNP criteria_NNS for_IN discordant_JJ siblings_NNS are_VBP as_IN
            follows_VBZ :_: 1_LS )_) The_DT subject_NN has_VBZ attained_VBN his_PRP$ or_CC her_PRP$ 18_CD th_NN
            birthday_NN at_IN the_DT time_NN of_IN enrollment_NN ._. 2_LS )_) The_DT subject_NN has_VBZ
            2_CD or_CC more_RBR full_JJ siblings_NNS who_WP each_DT have_VBP had_VBN an_DT ischemic_JJ
            stroke_NN and_CC who_WP are_VBP participating_VBG in_IN the_DT study_NN ._. 3_LS )_) The_DT
            subject_JJ reports_NNS having_VBG no_DT medical_JJ history_NN of_IN stroke_NN or_CC
            transient_JJ ischemic_JJ attack_NN (_( TIA_NNP )_) and_CC denies_VBZ ever_RB having_VBG
            had_VBN symptoms_NNS of_IN stroke_NN ._. Because_IN a_DT SWISS_NNP proband_NN might_MD
            erroneously_RB believe_VB that_IN a_DT sibling_VBG never_RB had_VBD a_DT stroke_NN ,_,
            discordance_NN is_VBZ considered_VBN verified_VBN only_RB if_IN the_DT sibling_VBG
            can_MD be_VB contacted_VBN for_IN a_DT structured_VBN telephone_NN interview_NN
            and_CC gives_VBZ negative_JJ answers_NNS to_TO all_DT 8_CD items_NNS on_IN the_DT
            Questionnaire_NNP for_IN Verifying_NNP Stroke-_NNP Free_NNP Status_NNP (_( QVSFS_NNP )_)
            (_( Table_NNP 1_LS )_) [_NN 57_CD 58_CD ]_NN ._. Discordant_NNP siblings_NNS are_VBP excluded_VBN
            if_IN they_PRP are_VBP deemed_VBN unreliable_JJ historians_NNS in_IN the_DT opinion_NN
            of_IN the_DT interviewer_NN administering_VBG the_DT QVSFS_NNP on_IN the_DT basis_NN
            of_IN global_JJ impression_NN of_IN moderate_JJ or_CC severe_JJ impairment_NN
            of_IN speech_NN ,_, language_NN ,_, hearing_NN ,_, or_CC memory_NN ._.
          
        
        
          Recruitment_NNP goals_NNS
          We_PRP aim_VBP to_TO enroll_VB at_IN least_JJS 300_CD concordant_NN sibling_VBG pairs_NNS
          (_( 300_CD probands_NNS plus_CC 300_CD concordant_NN siblings_NNS )_) and_CC 200_CD
          discordant_JJ siblings_NNS (_( 800_CD total_JJ study_NN subjects_NNS )_) ._. Because_IN
          it_PRP is_VBZ likely_JJ that_IN not_RB all_DT concordant_NN siblings_NNS will_MD
          actually_RB participate_VB ,_, more_JJR than_IN 300_CD probands_NNS will_MD be_VB
          enrolled_VBN to_TO obtain_VB DNA_NNP from_IN 300_CD concordant_NN sibling_VBG
          pairs_NNS ._.
        
        
          Study_NN procedures_NNS
          
            Phase_NN I_PRP ._. Enrolling_NNP Probands_NNP and_CC Recruiting_NNP
            Siblings_NNP
            Screening_NNP and_CC enrollment_NN will_MD take_VB place_NN at_IN 50_CD
            participating_VBG centers_NNS in_IN the_DT United_NNP States_NNPS and_CC Canada_NNP
            (_( Appendix_NNP )_) ._. At_IN each_DT center_NN ,_, a_DT study_NN neurologist_NN screens_NNS
            all_DT patients_NNS with_IN a_DT possible_JJ diagnosis_NN of_IN ischemic_JJ
            stroke_NN to_TO identify_VB potential_JJ SWISS_NNP probands_NNS ,_, orders_NNS or_CC
            reviews_VBZ medical_JJ tests_NNS pertinent_JJ to_TO the_DT diagnosis_NN and_CC
            subtyping_VBG of_IN ischemic_JJ stroke_NN as_IN part_NN of_IN routine_JJ
            clinical_JJ practice_NN ,_, and_CC makes_VBZ a_DT new_JJ diagnosis_NN or_CC
            confirms_VBZ a_DT previous_JJ diagnosis_NN of_IN ischemic_JJ stroke_NN in_IN a_DT
            potential_JJ proband_NN ._. A_DT certified_VBN study_NN neurologist_NN
            classifies_VBZ the_DT final_JJ subtype_NN of_IN the_DT index_NN stroke_NN
            according_VBG to_TO TOAST_NNP criteria_NNS [_NN 51_CD ]_NN ._. To_TO obtain_VB
            certification_NN the_DT neurologist_NN reads_VBZ the_DT original_JJ
            manuscript_NN describing_VBG the_DT TOAST_NNP classification_NN system_NN
            and_CC scores_NNS various_JJ patients_NNS presented_VBN in_IN a_DT series_NN of_IN
            stanardized_JJ clinical_JJ vignettes_NNS according_VBG to_TO TOAST_NNP
            criteria_NNS ._. The_DT scores_NNS are_VBP compared_VBN with_IN reference_NN values_NNS
            generated_VBN by_IN a_DT consensus_NN of_IN the_DT SVC_NNP ._. The_DT investigator_NN
            receives_VBZ feedback_NN on_IN any_DT deviations_NNS from_IN reference_NN
            values_NNS and_CC is_VBZ required_VBN to_TO review_VB the_DT TOAST_NNP
            classification_NN system_NN and_CC retake_NN the_DT test_NN ._.
            The_DT local_JJ coordinator_NN or_CC study_NN neurologist_NN conducts_VBZ
            a_DT face-to-face_JJ interview_NN with_IN patients_NNS who_WP meet_VBP
            enrollment_NN criteria_NNS to_TO obtain_VB their_PRP$ medical_JJ history_NN and_CC
            to_TO explain_VB the_DT study_NN ._. If_IN patients_NNS agree_VBP to_TO participate_VB
            in_IN the_DT study_NN ,_, they_PRP sign_NN and_CC date_NN 2_CD copies_NNS of_IN the_DT
            informed_VBN consent_NN form_NN ,_, retaining_VBG 1_CD copy_NN for_IN themselves_PRP ._.
            The_DT local_JJ coordinator_NN completes_VBZ the_DT proband_NN case_NN report_NN
            forms_NNS (_( CRFs_NNP )_) ,_, assigns_VBZ a_DT SWISS_NNP study_NN number_NN to_TO the_DT
            proband_NN ,_, forwards_RB the_DT proband_NN CRFs_NNP to_TO the_DT Clinical_NNP
            Coordinating_NNP Center_NNP ,_, and_CC gives_VBZ the_DT proband_NN (_( or_CC
            surrogate_JJ )_) a_DT set_NN of_IN study_NN invitation_NN letters_NNS to_TO be_VB sent_VBN
            to_TO all_DT of_IN his_PRP$ or_CC her_PRP$ living_VBG full_JJ siblings_NNS ._. In_IN the_DT
            letter_NN ,_, siblings_NNS are_VBP asked_VBN to_TO indicate_VB whether_IN they_PRP are_VBP
            interested_JJ in_IN participating_VBG in_IN SWISS_NNP by_IN completing_VBG the_DT
            contact_NN information_NN section_NN and_CC sending_VBG it_PRP to_TO the_DT
            Clinical_NNP Coordinating_NNP Center_NNP ._. The_DT Center_NNP assigns_VBZ SWISS_NNP
            numbers_NNS to_TO all_DT siblings_NNS who_WP provide_VBP contact_NN
            information_NN ._.
          
          
            Phase_NN II_NNP ._. Verifying_NNP Concordance_NNP and_CC
            Discordance_NNP
            The_DT goal_NN of_IN Phase_NN II_NNP is_VBZ to_TO confirm_VB that_IN phenotyping_VBG
            of_IN siblings_NNS is_VBZ accurate_JJ ._.
            Discordance_NNP is_VBZ confirmed_VBN in_IN Phase_NN IIA_NNP ._. The_DT Clinical_NNP
            Coordinating_NNP Center_NNP contacts_NNS potentially_RB discordant_JJ
            siblings_NNS who_WP provide_VBP contact_NN information_NN ,_, obtains_NNS
            verbal_JJ consent_NN for_IN a_DT brief_JJ telephone_NN interview_NN ,_,
            administers_VBZ the_DT QVSFS_NNP (_( Table_NNP 1_LS )_) ,_, and_CC obtains_NNS a_DT
            standardized_JJ medical_JJ history_NN in_IN a_DT structured_VBN telephone_NN
            interview_NN ._. Siblings_NNP who_WP give_VBP negative_JJ answers_NNS to_TO the_DT
            QVSFS_NNP medical_JJ history_NN items_NNS but_CC who_WP give_VBP a_DT positive_JJ
            response_NN to_TO 1_CD or_CC more_JJR of_IN the_DT review-of-symptoms_JJ items_NNS
            are_VBP advised_VBN to_TO inform_VB their_PRP$ primary_JJ care_NN physician_NN of_IN
            their_PRP$ symptoms_NNS so_IN that_IN they_PRP can_MD be_VB evaluated_VBN
            accordingly_RB ._. Siblings_NNP who_WP respond_VBP positively_RB to_TO QVSFS_NNP
            item_NN 1_CD advance_NN to_TO Phase_NN IIB_NNP ._. If_IN all_DT of_IN the_DT QVSFS_NNP items_NNS
            are_VBP negative_JJ ,_, the_DT patient_NN is_VBZ considered_VBN a_DT verified_VBN
            discordant_JJ sibling_VBG ._. The_DT discordant_JJ sibling_VBG CRFs_NNP are_VBP
            completed_VBN during_IN the_DT telephone_NN interview_NN ,_, and_CC the_DT
            Clinical_NNP Coordinating_NNP Center_NNP sends_VBZ 2_CD copies_NNS of_IN the_DT
            Informed_NNP Consent_NNP Form_NNP (_( ICF_NNP )_) to_TO the_DT verified_VBN discordant_JJ
            sibling_VBG ,_, who_WP returns_VBZ 1_CD signed_VBD copy_NN to_TO the_DT Center_NNP and_CC
            retains_VBZ 1_CD copy_NN ._. Verified_NNP discordant_JJ siblings_NNS advance_VBP to_TO
            Phase_NN III_NNP of_IN the_DT study_NN ._.
            Concordance_NNP is_VBZ confirmed_VBN in_IN Phase_NN IIB_NNP ._. The_DT Clinical_NNP
            Coordinating_NNP Center_NNP sends_VBZ potentially_RB concordant_NN
            siblings_NNS a_DT Request_NNP for_IN Medical_NNP Records_NNPS Form_NN (_( RMRF_NNP )_) and_CC
            2_CD copies_NNS of_IN the_DT informed_VBN consent_NN form_NN to_TO sign_VB ,_, date_NN ,_,
            and_CC return_NN ._. The_DT RMRF_NNP is_VBZ a_DT slightly_RB modified_VBN
            study-specific_JJ version_NN of_IN the_DT official_JJ form_NN used_VBN by_IN
            Mayo_NNP Clinic_NNP for_IN routine_JJ patient_NN care_NN ._. Subjects_NNP return_NN 1_CD
            copy_NN of_IN the_DT signed_VBN form_NN in_IN a_DT pre-addressed_JJ ,_,
            postage-paid_JJ envelope_NN provided_VBN with_IN the_DT original_JJ form_NN
            and_CC retain_VB the_DT second_JJ copy_NN ._. The_DT Clinical_NNP Coordinating_NNP
            Center_NNP uses_VBZ the_DT signed_VBN form_NN to_TO request_VB medical_JJ records_NNS
            pertaining_VBG to_TO the_DT sibling_VBG index_NN stroke_NN ._. The_DT Center_NNP
            constructs_NNS a_DT file_NN of_IN medical_JJ records_NNS in_IN a_DT standardized_JJ ,_,
            subdivided_JJ sequence_NN (_( hospital_NN admission_NN notes_NNS and_CC
            discharge_NN summaries_NNS ;_: neurologic_JJ consultation_NN notes_NNS ;_:
            reports_NNS of_IN computed_JJ tomographic_JJ and_CC magnetic_JJ resonance_NN
            imaging_NN of_IN the_DT head_NN ;_: reports_NNS of_IN imaging_NN of_IN the_DT heart_NN by_IN
            transthoracic_JJ and_CC transesophageal_NN echocardiography_NN ;_:
            copies_NNS of_IN electrocardiograms_NNS ;_: reports_NNS of_IN imaging_NN of_IN
            cervicocephalic_JJ vasculature_NN by_IN angiography_NN using_VBG
            conventional_JJ ,_, computed_JJ tomographic_JJ ,_, or_CC magnetic_JJ
            resonance_NN techniques_NNS or_CC by_IN ultrasonography_NN ;_: and_CC reports_NNS
            of_IN blood_NN work_NN )_) ._.
            The_DT Clinical_NNP Coordinating_NNP Center_NNP submits_VBZ completed_VBN
            files_NNS on_IN potentially_RB concordant_NN siblings_NNS to_TO the_DT SVC_NNP on_IN
            a_DT weekly_JJ basis_NN ._. A_DT neurologist_NN member_NN of_IN the_DT SVC_NNP reviews_VBZ
            the_DT files_NNS and_CC attempts_NNS to_TO confirm_VB the_DT diagnosis_NN of_IN
            ischemic_JJ stroke_NN ,_, using_VBG a_DT standard_JJ stroke_NN work-up_JJ
            checklist_NN to_TO assist_VB with_IN and_CC document_VB a_DT systematic_JJ
            review_NN of_IN the_DT medical_JJ records_NNS ._. The_DT SVC_NNP may_MD instruct_VB the_DT
            Clinical_NNP Coordinating_NNP Center_NNP to_TO secure_VB additional_JJ
            medical_JJ records_NNS if_IN the_DT initial_JJ set_VBN fails_VBZ to_TO provide_VB
            sufficient_JJ evidence_NN to_TO confirm_VB the_DT diagnosis_NN of_IN
            ischemic_JJ stroke_NN ._. If_IN the_DT SVC_NNP neurologist_NN cannot_NN confirm_VBP
            the_DT diagnosis_NN of_IN stroke_NN ,_, the_DT potentially_RB concordant_NN
            sibling_VBG does_VBZ not_RB advance_VB in_IN the_DT study_NN ._. If_IN concordance_NN
            is_VBZ confirmed_VBN ,_, the_DT SVC_NNP neurologist_NN classifies_VBZ the_DT TOAST_NNP
            stroke_NN subtype_NN ,_, completes_VBZ the_DT CRFs_NNP for_IN the_DT concordant_NN
            sibling_VBG ,_, and_CC forwards_RB the_DT forms_NNS to_TO the_DT Clinical_NNP
            Coordinating_NNP Center_NNP ._.
            Although_IN as_RB many_JJ as_IN 10_CD %_NN of_IN the_DT concordant_NN siblings_NNS
            in_IN SWISS_NNP may_MD have_VB a_DT history_NN of_IN 2_CD or_CC more_JJR strokes_NNS ,_, the_DT
            SVC_NNP confirms_VBZ the_DT diagnosis_NN and_CC classifies_VBZ the_DT subtype_NN
            of_IN ischemic_JJ stroke_NN only_RB for_IN the_DT most_RBS recent_JJ stroke_NN for_IN
            which_WDT there_EX are_VBP records_NNS sufficient_JJ to_TO confirm_VB the_DT
            diagnosis_NN (_( the_DT sibling_VBG index_NN stroke_NN )_) ._. The_DT verified_VBN
            concordant_NN sibling_VBG then_RB advances_NNS to_TO Phase_NN III_NNP ._.
          
          
            Phase_NN III_NNP ._. Acquiring_NNP Blood_NNP for_IN Genetic_NNP
            Analysis_NNP
            Blood_NNP samples_NNS are_VBP taken_VBN only_RB when_WRB a_DT study_NN pedigree_NN
            is_VBZ complete_JJ ,_, i_NNP ._. e_SYM ._. ,_, clinical_JJ data_NNS and_CC ICF_NNP are_VBP available_JJ
            from_IN 1_CD proband_NN and_CC at_IN least_JJS 1_CD verified_VBN concordant_NN
            sibling_VBG ,_, with_IN or_CC without_IN 1_CD verified_VBN discordant_JJ sibling_VBG ._.
            If_IN the_DT diagnosis_NN of_IN ischemic_JJ stroke_NN cannot_NN be_VB verified_VBN
            for_IN any_DT sibling_VBG of_IN a_DT proband_NN ,_, the_DT clinical_JJ data_NN from_IN
            that_DT proband_NN are_VBP saved_VBN ,_, but_CC no_DT blood_NN samples_NNS are_VBP
            collected_VBN ._. When_WRB a_DT pedigree_NN is_VBZ complete_JJ ,_, the_DT Clinical_NNP
            Coordinating_NNP Center_NNP instructs_VBZ the_DT home_NN health_NN agency_NN to_TO
            collect_VB blood_NN samples_NNS from_IN all_DT pedigree_NN members_NNS ._. A_DT
            phlebotomist_NN from_IN the_DT home_NN health_NN agency_NN visits_VBZ the_DT
            subjects_NNS at_IN their_PRP$ homes_NNS ,_, obtains_NNS a_DT blood_NN sample_NN ,_, and_CC
            ships_NNS it_PRP to_TO the_DT DNA_NNP Bank_NNP ._.
          
          
            Phase_NN IV_NNP ._. Genome-wide_NNP Scan_NNP
            The_DT DNA_NNP Bank_NNP creates_VBZ cell_NN lines_NNS and_CC notifies_VBZ the_DT
            Genetics_NNP Laboratory_NNP when_WRB 300_CD concordant_NN sibling_VBG pair_NN
            specimens_NNS are_VBP ready_JJ for_IN analysis_NN ._. The_DT Genetics_NNP
            Laboratory_NNP then_RB performs_VBZ the_DT genome-wide_JJ scan_VB ._.
          
        
        
          Measures_NNS of_IN outcome_NN
          The_DT primary_JJ outcome_NN is_VBZ the_DT degree_NN of_IN linkage_NN between_IN
          the_DT stroke_NN phenotype_NN and_CC genetic_JJ markers_NNS as_IN measured_VBN by_IN
          the_DT proportion_NN of_IN alleles_NNS shared_VBN by_IN concordant_NN sibling_VBG
          pairs_NNS (_( accumulated_VBN over_IN all_DT pairs_NNS at_IN each_DT marker_NN )_) ._.
        
        
          Clinical_NNP database_NN
          For_IN each_DT proband_NN ,_, we_PRP collect_VBP name_NN ,_, date_NN of_IN birth_NN ,_,
          gender_NN ,_, race_NN ,_, home_NN address_NN ,_, home_NN phone_NN number_NN ,_, e-mail_JJ
          address_NN ,_, and_CC alternative_JJ contact_NN information_NN ._. We_PRP record_NN
          the_DT enrolling_VBG investigator_NN 's_POS study_NN number_NN and_CC the_DT study_NN
          center_NN number_NN to_TO assure_VB accurate_JJ attribution_NN of_IN efforts_NNS
          and_CC to_TO make_VB it_PRP possible_JJ to_TO verify_VB entries_NNS in_IN CRFs_NNP with_IN
          source_NN documents_NNS ._. Data_NNP are_VBP collected_VBN on_IN stroke_NN risk_NN
          factors_NNS and_CC medical_JJ history_NN ,_, date_NN of_IN onset_NN of_IN stroke_NN
          symptoms_NNS ,_, TOAST_NNP stroke_NN subtype_NN ,_, and_CC the_DT total_JJ number_NN of_IN
          living_VBG full_JJ siblings_NNS ._.
          The_DT following_VBG information_NN is_VBZ collected_VBN on_IN all_DT living_VBG
          full_JJ siblings_NNS who_WP return_VBP sibling_VBG response_NN letters_NNS :_: name_NN ,_,
          date_NN of_IN birth_NN ,_, gender_NN ,_, name_NN of_IN the_DT proband_NN they_PRP are_VBP
          related_VBN to_TO ,_, twin_JJ status_NN ,_, home_NN address_NN ,_, home_NN phone_NN number_NN ,_,
          e-mail_JJ address_NN ,_, alternative_JJ contact_NN information_NN ,_, and_CC
          standardized_JJ risk_NN factor_NN and_CC medical_JJ history_NN ._.
          In_IN addition_NN ,_, for_IN each_DT concordant_NN sibling_VBG ,_, we_PRP record_NN
          date_NN of_IN review_NN of_IN outside_IN medical_JJ records_NNS ,_, a_DT stroke_NN
          work-up_JJ checklist_NN addressing_VBG medical_JJ reports_NNS reviewed_VBN by_IN
          the_DT physician_NN member_NN of_IN the_DT SVC_NNP who_WP confirms_VBZ stroke_NN
          concordance_NN ,_, date_NN of_IN onset_NN of_IN index_NN stroke_NN (_( and_CC of_IN first_JJ
          stroke_NN ,_, if_IN sibling_VBG had_VBN more_JJR than_IN one_CD )_) ,_, TOAST_NNP subtype_NN of_IN
          index_NN stroke_NN ,_, and_CC responses_NNS to_TO all_DT items_NNS contained_VBD in_IN the_DT
          QVSFS_NNP ._. For_IN discordant_JJ siblings_NNS ,_, we_PRP record_NN responses_NNS to_TO
          all_DT items_NNS contained_VBD in_IN the_DT QVSFS_NNP ._.
        
        
          Genotyping_NNP
          Local_JJ centers_NNS receive_VBP blood_NN shipping_VBG kits_NNS ,_, including_VBG a_DT
          Vacutainer_NNP for_IN blood_NN ,_, by_IN mail_NN at_IN the_DT start_NN of_IN SWISS_NNP ,_, and_CC
          the_DT Clinical_NNP Coordinating_NNP Center_NNP will_MD restock_NN the_DT supply_NN
          on_IN a_DT continuing_VBG basis_NN ._. Used_VBN kits_NNS are_VBP shipped_VBN overnight_JJ to_TO
          the_DT DNA_NNP Bank_NNP for_IN processing_NN ._. Lymphoblastoid_NNP cell_NN lines_NNS
          will_MD be_VB generated_VBN from_IN peripheral_JJ blood_NN leukocytes_NNS and_CC
          DNA_NNP extracted_VBD using_VBG routine_JJ methods_NNS ._. DNA_NN analysis_NN will_MD
          begin_VB after_IN the_DT 300_CD th_NN concordant_NN sibling_VBG pair_NN is_VBZ
          enrolled_VBN ,_, which_WDT we_PRP anticipate_VBP to_TO be_VB at_IN the_DT end_NN of_IN year_NN 4_CD ._.
          At_IN that_DT time_NN ,_, the_DT DNA_NNP Bank_NNP will_MD ship_VB at_IN least_JJS 50_CD μg_NN of_IN
          DNA_NNP to_TO the_DT Genetics_NNP Laboratory_NNP ._.
          At_IN the_DT Genetics_NNP Laboratory_NNP ,_, the_DT DNA_NNP will_MD be_VB plated_JJ
          onto_IN 384_CD -_: well_RB plates_NNS for_IN marker_NN genotyping_VBG ._. The_DT ABI_NNP
          Genescan_NNP /_NN Genotyper_NNP system_NN will_MD be_VB employed_VBN in_IN
          semiautomated_JJ fluorescent_NN genotyping_VBG ,_, comparing_VBG fragment_NN
          sizes_NNS to_TO an_DT internal_JJ standard_NN of_IN CEPH_NNP DNA_NNP ._. An_DT ABI_NNP 377_CD with_IN
          96_CD wells_NNS generates_VBZ the_DT marker_NN data_NN ._. All_DT genotypes_NNS will_MD be_VB
          scored_VBN blind_JJ to_TO phenotype_NN ._. Two_CD hundred_CD thirty-seven_JJ
          microsatellite_NN markers_NNS ,_, obtained_VBN from_IN Genethon_NNP ,_, CHLC_NNP ,_, and_CC
          GDB_NNP (_( 106_CD di-_NN ,_, 21_CD tri-_NN ,_, and_CC 110_CD tetranucleotides_NNS )_) ,_, will_MD be_VB
          typed_VBN in_IN all_DT sibling_VBG pairs_NNS ._. These_DT 237_CD markers_NNS have_VBP been_VBN
          sorted_VBN into_IN 30_CD panels_NNS ._. We_PRP will_MD run_VB 92_CD samples_NNS per_IN gel_NN
          (_( with_IN 4_CD lanes_NNS for_IN controls_NNS )_) ;_: estimating_VBG ~_NN 920_CD samples_NNS at_IN
          30_CD panels_NNS ,_, 300_CD gels_NNS will_MD be_VB needed_VBN ._. Allowing_VBG for_IN reruns_NNS
          and_CC data_NNS loss_NN ,_, we_PRP estimate_VBP that_IN 400_CD gels_NNS will_MD be_VB required_VBN
          to_TO complete_VB this_DT task_NN and_CC extract_VB greater_JJR than_IN 90_CD %_NN of_IN the_DT
          genetic_JJ data_NN ._. The_DT average_JJ distance_NN between_IN adjacent_JJ
          markers_NNS in_IN this_DT panel_NN series_NN is_VBZ 16_CD ._. 3_LS cM_NN (_( 1_CD -_: 40_CD cM_NN )_) ._.
          Average_JJ heterozygosity_NN will_MD be_VB calculated_VBN ._. The_DT CRI-MAP_NNP
          program_NN will_MD determine_VB intermarker_NN distances_NNS and_CC will_MD
          also_RB be_VB used_VBN to_TO form_VB the_DT study-specific_JJ genetic_JJ map_NN ._. A_DT
          genotype_NN database_NN (_( Megabase_NNP )_) will_MD be_VB used_VBN to_TO check_VB the_DT
          binning_VBG of_IN alleles_NNS ,_, convert_VB allele_NN sizes_NNS to_TO whole_JJ
          numbers_NNS ,_, and_CC (_( where_WRB possible_JJ )_) to_TO test_VB for_IN non-_NN Mendelian_NNP
          inheritance_NN ._. Megabase_NNP will_MD store_VB all_DT relevant_JJ
          genotypic_JJ /_NN phenotypic_JJ data_NNS and_CC produce_VB all_DT files_NNS needed_VBN
          for_IN statistical_JJ analysis_NN ._.
        
        
          Cell_NNP lines_NNS
          We_PRP regard_VBP banking_NN of_IN samples_NNS to_TO be_VB a_DT key_JJ element_NN of_IN
          this_DT study_NN ._. Collection_NNP of_IN clinical_JJ samples_NNS is_VBZ expensive_JJ
          and_CC time_NN consuming_NN ,_, and_CC it_PRP is_VBZ probable_JJ that_DT progress_NN in_IN
          identifying_VBG genes_NNS involved_VBN in_IN stroke_NN will_MD be_VB incremental_JJ ._.
          For_IN genes_NNS of_IN smaller_JJR effect_NN ,_, very_RB large_JJ sample_NN sizes_NNS are_VBP
          likely_JJ to_TO be_VB needed_VBN ._. Having_VBG these_DT resources_NNS available_JJ
          will_MD ensure_VB that_IN future_JJ work_NN can_MD build_VB effectively_RB on_IN the_DT
          work_NN we_PRP present_JJ here_RB ._. Epstein-_NNP Barr_NNP virus-transformed_JJ
          lymphoblastoid_NN cell_NN lines_NNS will_MD be_VB used_VBN ._.
        
        
          Statistical_NNP methods_NNS
          For_IN the_DT concordant_NN sibling_VBG pair_NN design_NN ,_, the_DT proportion_NN
          of_IN alleles_NNS shared_VBN by_IN the_DT concordant_NN sibling_VBG pairs_NNS
          (_( accumulated_VBN over_IN all_DT pairs_NNS at_IN that_DT marker_NN )_) is_VBZ the_DT
          statistic_NN that_WDT determines_VBZ evidence_NN for_IN linkage_NN between_IN
          the_DT stroke_NN phenotype_NN and_CC the_DT genetic_JJ marker_NN ._. If_IN only_RB
          concordant_NN sibling_VBG pairs_NNS are_VBP collected_VBN ,_, a_DT maximum_NN of_IN only_RB
          4_CD alleles_NNS can_MD be_VB identified_VBN ._. The_DT third_JJ (_( discordant_JJ )_)
          sibling_VBG is_VBZ collected_VBN for_IN purposes_NNS of_IN determining_VBG
          potential_JJ nonpaternities_NNS in_IN a_DT sibship_NN (_( more_JJR than_IN 4_CD
          alleles_NNS )_) and_CC for_IN better_JJR estimating_VBG the_DT proportion_NN of_IN
          alleles_NNS shared_VBN that_WDT are_VBP identical_JJ by_IN state_NN (_( in_IN the_DT
          absence_NN of_IN parents_NNS )_) ._.
          Traditional_JJ applications_NNS of_IN gene_NN mapping_NN have_VBP used_VBN
          families_NNS in_IN which_WDT the_DT trait_NN (_( disease_NN )_) is_VBZ transmitted_VBN in_IN a_DT
          clearly_RB Mendelian_NNP fashion_NN ._. For_IN more_RBR complex_JJ traits_NNS ,_, the_DT
          inheritance_NN pattern_NN does_VBZ not_RB fit_VB a_DT single-gene_JJ model_NN ,_, and_CC
          methods_NNS that_WDT assume_VBP a_DT genetic_JJ model_NN may_MD provide_VB erroneous_JJ
          results_NNS [_NN 59_CD ]_NN ._. Ischemic_NNP stroke_NN clearly_RB demonstrates_VBZ
          familial_NN aggregation_NN ,_, yet_RB no_DT single-gene_JJ model_NN of_IN
          transmission_NN is_VBZ consistent_JJ with_IN the_DT family_NN data_NN ._. In_IN this_DT
          project_NN ,_, we_PRP propose_VBP to_TO use_VB model-independent_JJ (_( relative_JJ
          pair_NN )_) analysis_NN ,_, a_DT method_NN that_WDT is_VBZ designed_VBN to_TO detect_VB
          linkage_NN without_IN the_DT specification_NN of_IN an_DT underlying_VBG
          genetic_JJ model_NN and_CC that_DT is_VBZ robust_JJ to_TO contributions_NNS by_IN
          environmental_JJ variation_NN ._. The_DT methods_NNS of_IN analysis_NN for_IN
          determination_NN of_IN risk_NN factor_NN loci_NN will_MD mainly_RB use_VB the_DT
          SPLINK_NNP and_CC MAPMAKER_NNP /_NN SIBS_NNP programs_NNS [_NN 60_CD 61_CD ]_NN ._.
        
        
          Estimates_NNS of_IN power_NN to_TO detect_VB linkage_NN
          For_IN concordant_NN sibling_VBG pair_NN studies_NNS ,_, Risch_NNP [_NN 62_CD 63_CD ]_NN
          demonstrated_VBN that_IN the_DT fraction_NN K_NNP 
          r_LS /_NN K_NNP 
          p_NN ,_, defined_VBN as_IN the_DT risk_NN ratio_NN λ_NN 
          r_LS for_IN a_DT type-_NN R_NN relative_JJ ,_, can_MD be_VB used_VBN
          to_TO model_VB the_DT probable_JJ modes_NNS of_IN transmission_NN for_IN a_DT complex_JJ
          disease_NN ._. Thus_RB ,_, under_IN a_DT given_VBN model_NN ,_, the_DT value_NN of_IN λ_NN 
          r_LS should_MD decrease_VB in_IN a_DT model-specific_JJ
          manner_NN for_IN each_DT decreasing_VBG degree_NN of_IN unilineal_NN
          relationship_NN ,_, and_CC this_DT expected_JJ value_NN can_MD then_RB be_VB
          contrasted_VBN with_IN recurrence_NN risks_NNS obtained_VBN from_IN a_DT set_NN of_IN
          relatives_NNS (_( monozygotic_JJ twins_NNS ,_, dizygotic_JJ twins_NNS ,_, siblings_NNS ,_,
          offspring_NN ,_, second-degree_JJ relatives_NNS ,_, etc_FW ._. )_) ._. For_IN a_DT
          single-locus_JJ model_NN ,_, therefore_RB ,_, the_DT value_NN of_IN (_( λ_NN 
          r_LS -_: 1_LS )_) should_MD decrease_VB by_IN a_DT factor_NN of_IN
          2_CD ,_, and_CC a_DT multiplicative_JJ model_NN predicts_VBZ risk_NN on_IN the_DT basis_NN
          of_IN the_DT product_NN of_IN the_DT individual_JJ factors_NNS ._.
          Risch_NNP [_NN 63_CD ]_NN extended_VBD the_DT approach_NN of_IN Suarez_NNP et_CC al_NN [_NN
          64_CD ]_NN to_TO include_VB any_DT relative_JJ pair_NN ._. On_IN the_DT basis_NN of_IN this_DT
          formulation_NN ,_, the_DT power_NN to_TO detect_VB linkage_NN can_MD be_VB obtained_VBN
          for_IN relative_JJ (_( sibling_VBG )_) pairs_NNS ._. For_IN concordant_NN sibling_VBG
          pairs_NNS ,_, assuming_VBG that_IN the_DT candidate_NN locus_JJ is_VBZ near_IN a_DT stroke_NN
          susceptibility_NN locus_JJ (_( θ_NN >_NN 0_CD )_) ,_, power_NN depends_VBZ upon_IN λ_NN 
          s_VBZ (_( sibling_VBG recurrence_NN risk_NN )_) and_CC λ_NN 
          o_NN (_( offspring_NN recurrence_NN risk_NN )_) ._. If_IN
          there_EX is_VBZ little_JJ dominance_NN effect_NN ,_, then_RB λ_NN 
          s_VBZ =_SYM λ_NN 
          o_NN ,_, and_CC hence_RB the_DT power_NN can_MD be_VB
          computed_JJ on_IN the_DT basis_NN of_IN sibling_VBG recurrence_NN risk_NN ._. For_IN
          other_JJ pairs_NNS of_IN relatives_NNS ,_, Risch_NNP [_NN 63_CD ]_NN has_VBZ shown_VBN that_IN the_DT
          single_JJ parameter_NN λ_NN 
          o_NN is_VBZ sufficient_JJ to_TO specify_VB power_NN (_( and_CC
          θ_NN ,_, if_IN θ_NN >_NN 0_CD )_) ._. The_DT recurrence_NN risk_NN data_NNS in_IN relatives_NNS
          are_VBP sparse_NN for_IN stroke_NN ._. Data_NNS from_IN Framingham_NNP suggest_VBP that_IN
          a_DT reasonable_JJ estimate_NN of_IN λ_NN 
          s_VBZ for_IN stroke_NN may_MD range_VB from_IN 2_CD to_TO
          5_CD ._.
          We_PRP assume_VBP that_IN the_DT genetic_JJ markers_NNS used_VBN have_VBP
          polymorphic_JJ information_NN content_NN (_( PIC_NNP )_) equivalent_JJ to_TO that_DT
          of_IN an_DT equiprobable_JJ 4_CD -_: allele_NN system_NN ,_, yielding_VBG a_DT PIC_NNP of_IN
          about_IN 70_CD %_NN ._. The_DT sample_NN size_NN required_VBN to_TO determine_VB a_DT given_VBN
          power_NN is_VBZ inversely_RB proportional_JJ to_TO the_DT PIC_NNP of_IN the_DT
          markers_NNS ;_: thus_RB ,_, a_DT sample_NN of_IN 300_CD concordant_NN sibling_VBG pairs_NNS
          genotyped_JJ at_IN a_DT marker_NN with_IN PIC_NNP of_IN 70_CD %_NN would_MD be_VB equivalent_JJ
          to_TO a_DT fully_RB informative_JJ marker_NN typed_VBN on_IN 210_CD concordant_NN
          pairs_NNS ._. In_IN our_PRP$ consideration_NN of_IN power_NN ,_, therefore_RB ,_, we_PRP
          consider_VBP a_DT marker_NN with_IN incomplete_JJ information_NN ,_, and_CC the_DT
          initial_JJ analyses_NNS will_MD comprise_VB pairwise_NN analyses_NNS ._.
          Application_NNP of_IN multipoint_NN (_( interval_NN )_) mapping_NN methods_NNS will_MD
          further_VB increase_VB power_NN [_NN 65_CD ]_NN ._. Formal_NNP analyses_NNS with_IN
          MAPMAKER_NNP /_NN SIBS_NNP or_CC GeneHunter_NNP will_MD add_VB further_JJ power_NN by_IN
          means_NNS of_IN the_DT multipoint_NN method_NN ._. Using_VBG this_DT approach_NN ,_, we_PRP
          have_VBP estimated_VBN power_NN for_IN a_DT set_NN of_IN 300_CD sibling_VBG pairs_NNS
          concordant_NN for_IN stroke_NN (_( equivalent_JJ to_TO 210_CD pairs_NNS with_IN fully_RB
          informative_JJ markers_NNS but_CC without_IN parents_NNS )_) ._. With_IN these_DT
          estimates_NNS ,_, we_PRP should_MD have_VB ample_JJ power_NN to_TO detect_VB linkage_NN
          between_IN a_DT marker_NN and_CC a_DT moderately_RB strong_JJ susceptibility_NN
          locus_JJ ,_, especially_RB for_IN locus-specific_JJ sib_NN risks_NNS greater_JJR
          than_IN 3_CD ._.
          For_IN a_DT homogeneous_JJ single_JJ disease_NN susceptibility_NN locus_JJ ,_,
          the_DT power_NN to_TO detect_VB linkage_NN with_IN our_PRP$ expected_VBN 300_CD
          concordant_NN sibling_VBG pairs_NNS generally_RB approaches_VBZ 100_CD %_NN (_( Table_NNP
          3_LS )_) ._. If_IN stroke_NN susceptibility_NN is_VBZ attributable_JJ to_TO several_JJ
          loci_NN ,_, the_DT risk_NN becomes_VBZ dependent_JJ upon_IN the_DT nature_NN of_IN the_DT
          contributions_NNS (_( additive_JJ or_CC epistatic_JJ )_) ,_, and_CC the_DT loci_NN are_VBP
          more_RBR difficult_JJ to_TO identify_VB ._. Recent_JJ efforts_NNS utilizing_VBG
          analysis_NN of_IN genome_NN scan_VB data_NNS conditional_JJ on_IN the_DT evidence_NN
          for_IN linkage_NN of_IN a_DT major_JJ susceptibility_NN factor_NN show_NN promise_NN
          [_NN 66_CD ]_NN ._. With_IN 300_CD concordant_NN sibling_VBG pairs_NNS ,_, we_PRP have_VBP over_IN
          70_CD %_NN power_NN to_TO detect_VB linkage_NN with_IN a_DT genome-wide_JJ
          significance_NN of_IN 
          P_NN =_SYM 0_CD ._. 00022_CD and_CC locus-specific_JJ risk_NN
          of_IN λ_NN 
          s_VBZ =_SYM 1_CD ._. 6_CD ._. As_IN was_VBD demonstrated_VBN in_IN the_DT
          discordant_JJ sibling-pair_JJ analyses_NNS ,_, we_PRP may_MD have_VB substantial_JJ
          power_NN to_TO detect_VB linkage_NN using_VBG a_DT complementary_JJ analytic_JJ
          approach_NN ,_, so_IN that_IN the_DT addition_NN of_IN even_RB 100_CD discordant_JJ
          siblings_NNS to_TO the_DT concordant_NN sibling_VBG pairs_NNS may_MD provide_VB
          additional_JJ insight_NN on_IN linkage_NN ._.
        
      
      
        Discussion_NNP
        It_PRP is_VBZ clearly_RB of_IN importance_NN to_TO define_VB genetic_JJ risk_NN
        factor_NN loci_NN for_IN stroke_NN ._. Defining_VBG such_JJ loci_NN should_MD
        eventually_RB enable_VB us_PRP to_TO determine_VB prospectively_RB those_DT who_WP
        are_VBP at_IN high_JJ risk_NN for_IN the_DT disease_NN and_CC to_TO counsel_VB and_CC treat_VB
        them_PRP based_VBN on_IN this_DT knowledge_NN :_: in_IN addition_NN ,_, these_DT risk_NN
        factor_NN loci_NN may_MD help_VB in_IN the_DT identification_NN of_IN new_JJ drug_NN
        targets_NNS for_IN effective_JJ treatment_NN of_IN this_DT prevalent_JJ disease_NN ._.
        However_RB ,_, special_JJ safeguards_NNS must_MD be_VB in_IN place_NN to_TO protect_VB the_DT
        rights_NNS of_IN subjects_NNS involved_VBN in_IN genetic_JJ research_NN ._. If_IN genetic_JJ
        information_NN is_VBZ improperly_RB safeguarded_VBN ,_, misuse_NN could_MD
        adversely_RB influence_VB insurability_NN [_NN 67_CD ]_NN and_CC employability_NN [_NN
        68_CD ]_NN of_IN subjects_NNS and_CC could_MD stigmatize_NN individuals_NNS or_CC groups_NNS
        [_NN 69_CD ]_NN ._. For_IN this_DT study_NN ,_, we_PRP have_VBP adopted_VBN many_JJ of_IN the_DT
        practical_JJ suggestions_NNS of_IN Merz_NNP and_CC colleagues_NNS [_NN 70_CD ]_NN
        regarding_VBG the_DT ethical_JJ use_NN of_IN human_JJ tissue_NN ._. For_IN linking_VBG
        purposes_NNS ,_, we_PRP use_VBP special_JJ study-specific_JJ codes_NNS ,_, rather_RB than_IN
        medical_JJ record_NN numbers_NNS ,_, Social_NNP Security_NNP numbers_NNS ,_, or_CC an_DT
        easily_RB decoded_JJ combination_NN of_IN initials_NNS and_CC birth_NN dates_NNS ._.
        Access_NNP to_TO linking_VBG files_NNS is_VBZ restricted_VBN to_TO an_DT as-needed_JJ basis_NN
        only_RB ,_, and_CC the_DT files_NNS are_VBP deleted_VBN when_WRB they_PRP are_VBP no_RB longer_RB
        needed_VBN ._. The_DT study_NN mandates_VBZ a_DT strictly_RB unidirectional_NN flow_NN
        of_IN information_NN ._. This_DT means_VBZ that_IN clinical_JJ data_NNS are_VBP used_VBN for_IN
        research_NN purposes_NNS ,_, but_CC research_NN data_NNS are_VBP not_RB used_VBN for_IN
        clinical_JJ purposes_NNS ._. This_DT restriction_NN on_IN the_DT use_NN of_IN the_DT SWISS_NNP
        data_NN set_VBN is_VBZ based_VBN on_IN our_PRP$ recognition_NN that_IN unique_JJ clinical_JJ
        obligations_NNS accompany_VB the_DT provision_NN of_IN predictive_JJ genetic_JJ
        test_NN results_NNS to_TO individual_JJ patients_NNS [_NN 71_CD ]_NN ._.
        Recently_RB ,_, there_EX has_VBZ been_VBN intense_JJ debate_NN in_IN the_DT United_NNP
        States_NNPS at_IN the_DT federal_JJ level_NN over_IN the_DT privacy_NN rights_NNS of_IN
        pedigree_NN members_NNS with_IN respect_NN to_TO genetic_JJ research_NN ._. For_IN this_DT
        study_NN ,_, we_PRP have_VBP adopted_VBN the_DT position_NN that_IN every_DT member_NN of_IN a_DT
        pedigree_NN has_VBZ the_DT right_NN to_TO refuse_VB to_TO have_VB personal_JJ
        information_NN such_JJ as_IN name_NN ,_, address_VB ,_, and_CC medical_JJ history_NN
        recorded_VBN in_IN a_DT research_NN database_NN ._. This_DT right_JJ cannot_NN be_VB
        waived_VBN by_IN other_JJ members_NNS of_IN the_DT pedigree_NN [_NN 72_CD ]_NN ._. Therefore_RB ,_,
        probands_NNS or_CC their_PRP$ noninvestigator_NN surrogates_NNS invite_VB other_JJ
        family_NN members_NNS to_TO participate_VB ._. Siblings_NNP who_WP are_VBP interested_JJ
        in_IN participating_VBG voluntarily_RB provide_VB investigators_NNS with_IN
        their_PRP$ name_NN ,_, address_VB ,_, and_CC telephone_NN number_NN ._.
        Identifying_NNP the_DT genetic_JJ basis_NN of_IN diseases_NNS with_IN complex_JJ
        modes_NNS of_IN inheritance_NN is_VBZ a_DT daunting_JJ task_NN ,_, and_CC it_PRP is_VBZ likely_JJ
        that_IN a_DT variety_NN of_IN approaches_NNS will_MD be_VB necessary_JJ to_TO elucidate_NN
        the_DT genetic_JJ basis_NN of_IN human_JJ stroke_NN ._. Genomics_NNP has_VBZ been_VBN
        applied_VBN to_TO animal_NN models_NNS of_IN stroke_NN and_CC yielded_VBD discoveries_NNS
        about_IN loci_NN that_WDT correlate_VBP with_IN stroke_NN risk_NN ._. For_IN example_NN ,_,
        Rubattu_NNP and_CC colleagues_NNS [_NN 73_CD ]_NN identified_VBD 3_CD major_JJ
        quantitative_JJ trait_NN loci_NN in_IN the_DT F_NN 2_CD cross_NN of_IN stroke-prone_JJ and_CC
        spontaneously_RB hypertensive_JJ rats_NNS ._. Conducting_NNP adequately_RB
        powered_VBN genomics_NNS studies_NNS of_IN stroke_NN in_IN humans_NNS is_VBZ
        considerably_RB more_JJR challenging_VBG ._.
        The_DT central_JJ approach_NN this_DT study_NN takes_VBZ is_VBZ to_TO identify_VB
        areas_NNS of_IN the_DT genome_NN that_IN siblings_NNS affected_VBN by_IN stroke_NN share_NN
        more_RBR often_RB than_IN one_PRP would_MD expect_VB by_IN chance_NN ._. The_DT strength_NN of_IN
        this_DT approach_NN is_VBZ its_PRP$ theoretical_JJ robustness_NNS ,_, because_IN the_DT
        methods_NNS make_VBP relatively_RB few_JJ assumptions_NNS about_IN either_DT the_DT
        genetic_JJ architecture_NN of_IN the_DT population_NN in_IN which_WDT the_DT disease_NN
        is_VBZ studied_VBN or_CC about_IN the_DT disease_NN risk_NN ._. The_DT weaknesses_NNS of_IN the_DT
        approach_NN are_VBP its_PRP$ relative_JJ lack_NN of_IN power_NN and_CC the_DT low_JJ
        resolution_NN of_IN the_DT linkage_NN peaks_NNS identified_VBN ._. In_IN addition_NN ,_,
        the_DT logistical_JJ problem_NN of_IN obtaining_VBG DNA_NNP samples_NNS from_IN
        clinically_RB well-characterized_JJ members_NNS of_IN a_DT cohort_NN of_IN stroke_NN
        pedigrees_NNS can_MD be_VB a_DT daunting_JJ task_NN ._.
        Although_IN our_PRP$ primary_JJ analytic_JJ methods_NNS will_MD focus_VB on_IN the_DT
        concordant_NN pair_NN design_NN ,_, we_PRP will_MD also_RB use_VB a_DT complementary_JJ
        and_CC related_VBN approach_NN ,_, the_DT discordant_JJ sibling_VBG pair_NN method_NN ._.
        This_DT method_NN essentially_RB searches_VBZ for_IN areas_NNS of_IN the_DT genome_NN
        that_WDT are_VBP shared_VBN less_RBR often_RB than_IN one_PRP would_MD expect_VB by_IN chance_NN ._.
        Discordant_NNP siblings_NNS are_VBP generally_RB easier_JJR to_TO collect_VB because_IN
        they_PRP are_VBP more_RBR frequent_JJ than_IN concordant_NN siblings_NNS in_IN a_DT
        disease_NN such_JJ as_IN stroke_NN ._. As_IN demonstrated_VBN in_IN the_DT case_NN of_IN
        diabetic_JJ nephropathy_NN [_NN 74_CD ]_NN ,_, the_DT discordant_JJ sibling_VBG pair_NN
        approach_NN can_MD have_VB greater_JJR power_NN than_IN the_DT concordant_NN sibling_VBG
        pair_NN approach_NN in_IN certain_JJ situations_NNS ._. However_RB ,_, the_DT
        discordant_JJ sibling_VBG pair_NN approach_NN is_VBZ often_RB less_RBR efficient_JJ
        than_IN the_DT concordant_NN sibling_VBG method_NN because_IN of_IN the_DT
        uncertainty_NN of_IN the_DT final_JJ diagnostic_JJ status_NN of_IN the_DT
        unaffected_JJ sibling_VBG ._. Discordant_NNP siblings_NNS might_MD have_VB
        subclinical_JJ (_( radiographic_JJ )_) stroke_NN or_CC be_VB discordant_JJ only_RB
        because_IN of_IN their_PRP$ relative_JJ youth_NN ._. Furthermore_RB ,_, resource_NN
        limitations_NNS in_IN this_DT study_NN prevent_VBP the_DT collection_NN of_IN blood_NN
        from_IN more_JJR than_IN 1_CD discordant_JJ sibling_VBG for_IN each_DT concordant_NN
        pair_NN ._.
        An_DT alternative_JJ design_NN to_TO one_CD using_VBG affected_VBN relative_JJ
        pairs_NNS is_VBZ that_IN of_IN genome-wide_JJ association_NN in_IN subjects_NNS with_IN
        ischemic_JJ stroke_NN (_( cases_NNS )_) ascertained_JJ without_IN respect_NN to_TO
        family_NN history_NN compared_VBN with_IN nonstroke_NN controls_NNS for_IN
        frequency_NN of_IN numerous_JJ ,_, densely_RB spaced_JJ genetic_JJ markers_NNS
        (_( single_JJ nucleotide_NN polymorphisms_NNS or_CC SNPs_NNP )_) ._. Although_IN the_DT
        cases_NNS and_CC controls_NNS are_VBP collected_VBN more_RBR easily_RB than_IN
        concordant_NN sibling_VBG pairs_NNS ,_, this_DT approach_NN also_RB has_VBZ
        limitations_NNS ._. First_LS ,_, the_DT case-control_JJ approach_NN is_VBZ not_RB robust_JJ
        to_TO differential_NN environmental_JJ contribution_NN ,_, so_IN that_DT
        heterogeneity_NN between_IN case_NN and_CC control_NN exposure_NN could_MD
        result_VB in_IN spurious_JJ association_NN ._. Second_JJ ,_, unlike_IN the_DT
        concordant_NN sibling_VBG pair_NN approach_NN ,_, controls_NNS are_VBP "_'' unaffected_JJ "_''
        only_RB at_IN time_NN of_IN collection_NN ._. The_DT control_NN sample_NN actually_RB
        represents_VBZ a_DT mixture_NN of_IN subjects_NNS who_WP will_MD never_RB have_VB an_DT
        ischemic_JJ stroke_NN and_CC those_DT who_WP will_MD eventually_RB have_VB an_DT
        ischemic_JJ stroke_NN ._. Thus_RB ,_, true_JJ associations_NNS can_MD be_VB missed_VBN due_JJ
        to_TO misclassiflcation_NN ._. Third_NNP ,_, the_DT number_NN of_IN subjects_NNS to_TO be_VB
        collected_VBN to_TO provide_VB genome-wide_JJ significance_NN for_IN an_DT
        association_NN study_NN remains_VBZ large_JJ ,_, given_VBN the_DT number_NN of_IN SNPs_NNP
        to_TO be_VB genotyped_JJ across_IN the_DT genome_NN to_TO provide_VB 10_CD kb_NN to_TO 50_CD kb_NN
        spacing_VBG ._. To_TO address_VB the_DT "_'' multiple_JJ comparisons_NNS "_'' concern_NN with_IN
        thousands_NNS of_IN SNPs_NNP ,_, 10_CD ,_, 000_CD to_TO 20_CD ,_, 000_CD cases_NNS and_CC controls_NNS
        would_MD need_VB to_TO be_VB studied_VBN ._.
        Association_NN studies_NNS in_IN a_DT case_NN /_NN control_NN framework_NN have_VBP a_DT
        long_JJ history_NN in_IN stroke_NN etiology_NN research_NN ._. However_RB ,_, these_DT
        studies_NNS have_VBP been_VBN problematic_JJ because_IN until_IN now_RB they_PRP have_VBP
        only_RB allowed_VBN testing_NN for_IN the_DT known_VBN candidates_NNS ,_, and_CC they_PRP
        have_VBP been_VBN plagued_VBN by_IN false_JJ positives_NNS ._. With_IN the_DT completion_NN
        of_IN the_DT First_CD Draft_NNP of_IN the_DT Human_NNP Genome_NNP ,_, and_CC the_DT
        identification_NN of_IN haplotype_NN maps_NNS ,_, it_PRP may_MD be_VB that_IN this_DT
        approach_NN can_MD be_VB adapted_VBN to_TO a_DT whole_JJ genome_NN association_NN
        strategy_NN using_VBG prudently_RB positioned_VBN SNPs_NNP and_CC DNA_NNP samples_NNS
        banked_JJ in_IN SWISS_NNP ._.
        Much_JJ of_IN the_DT theoretical_JJ challenge_NN of_IN finding_VBG genetic_JJ
        risk_NN factors_NNS comes_VBZ from_IN the_DT heterogeneity_NN of_IN the_DT stroke_NN
        phenotype_NN ._. In_IN SWISS_NNP we_PRP are_VBP studying_VBG the_DT ultimate_JJ phenotype_NN
        of_IN ischemic_JJ stroke_NN ._. An_DT alternative_JJ approach_NN would_MD be_VB to_TO
        study_VB an_DT intermediate_JJ phenotype_NN ,_, such_JJ as_IN carotid_NN
        atherosclerosis_NNS ,_, with_IN the_DT hope_NN that_IN alleles_NNS underlying_VBG this_DT
        phenotype_NN play_VBP a_DT role_NN in_IN the_DT etiology_NN of_IN the_DT stroke_NN itself_PRP ._.
        Shifting_NNP the_DT object_NN of_IN investigation_NN from_IN ischemic_JJ stroke_NN
        to_TO carotid_NN atherosclerosis_NNS would_MD decrease_VB the_DT numbers_NNS of_IN
        subjects_NNS needed_VBN ._. Another_DT advantage_NN is_VBZ that_IN carotid_NN
        atherosclerosis_NNS can_MD be_VB treated_VBN as_IN a_DT quantitative_JJ trait_NN ._.
        However_RB ,_, using_VBG carotid_NN atherosclerosis_NNS as_IN an_DT intermediate_JJ
        phenotype_NN for_IN ischemic_JJ stroke_NN also_RB has_VBZ limitations_NNS ._. Perhaps_RB
        the_DT most_RBS important_JJ difficulty_NN is_VBZ that_IN high-grade_JJ carotid_NN
        atherosclerosis_NNS is_VBZ not_RB a_DT prerequisite_NN intermediate_JJ
        phenotype_NN in_IN most_JJS patients_NNS with_IN ischemic_JJ stroke_NN ._. The_DT
        large-artery_JJ atherosclerotic_JJ subtype_NN of_IN ischemic_JJ stroke_NN
        accounted_VBD for_IN only_RB 13_CD %_NN of_IN all_DT ischemic_JJ strokes_NNS in_IN a_DT recent_JJ
        population-based_JJ study_NN in_IN Bavaria_NNP ,_, Germany_NNP [_NN 75_CD ]_NN ._.
        Similarly_RB ,_, the_DT large-artery_JJ atherosclerotic_JJ subtype_NN
        accounted_VBD for_IN only_RB 16_CD %_NN of_IN all_DT ischemic_JJ strokes_NNS in_IN a_DT
        population-based_JJ study_NN in_IN Rochester_NNP ,_, Minnesota_NNP [_NN 76_CD ]_NN ._. In_IN
        addition_NN to_TO not_RB being_VBG a_DT mandatory_JJ intermediate_JJ phenotype_NN in_IN
        the_DT biological_JJ process_NN leading_VBG to_TO ischemic_JJ stroke_NN ,_, carotid_NN
        atherosclerosis_NNS is_VBZ itself_PRP a_DT complex_JJ phenotype_NN ._. Degree_NNP of_IN
        stenosis_NNS is_VBZ not_RB the_DT only_JJ factor_NN affecting_VBG symptomatology_NN of_IN
        an_DT atherosclerotic_JJ carotid_NN artery_NN [_NN 77_CD ]_NN ,_, and_CC important_JJ
        differences_NNS between_IN intracranial_NN and_CC cervical_JJ arteries_NNS in_IN
        the_DT genetics_NNS of_IN atherosclerosis_NNS may_MD go_VB unrecognized_JJ if_IN the_DT
        object_NN of_IN study_NN is_VBZ cervical_JJ carotid_NN atherosclerosis_NNS [_NN 78_CD ]_NN
        ._.
        Our_PRP$ study_NN directly_RB addresses_VBZ the_DT heterogeneity_NN of_IN the_DT
        ischemic_JJ stroke_NN phenotype_NN through_IN the_DT study-wide_JJ use_NN of_IN a_DT
        standardized_JJ ,_, validated_JJ ,_, and_CC widely_RB accepted_VBD system_NN of_IN
        classifying_VBG ischemic_JJ strokes_NNS based_VBN on_IN presumed_VBN etiology_NN ._.
        The_DT process_NN of_IN certification_NN minimizes_NNS variation_NN among_IN
        local_JJ center_NN physician_NN investigators_NNS in_IN assigning_VBG TOAST_NNP
        stroke_NN subtype_NN to_TO probands_NNS ._. The_DT process_NN of_IN central_JJ
        adjudication_NN minimizes_NNS the_DT variation_NN in_IN assigning_VBG TOAST_NNP
        subtype_NN to_TO concordant_NN siblings_NNS ._. Although_IN we_PRP recognize_VBP that_IN
        it_PRP may_MD be_VB of_IN value_NN for_IN future_JJ studies_NNS to_TO define_VB concordance_NN
        for_IN phenotype_NN by_IN ischemic_JJ stroke_NN subtype_NN ,_, we_PRP have_VBP chosen_VBN to_TO
        regard_VB that_DT approach_NN as_IN exploratory_JJ at_IN this_DT stage_NN ._.
        One_CD way_NN of_IN dealing_VBG with_IN the_DT logistic_JJ challenges_NNS inherent_JJ
        in_IN genetic_JJ studies_NNS is_VBZ to_TO collect_VB cases_NNS from_IN an_DT isolated_VBN
        population_NN ,_, such_JJ as_IN Iceland_NNP [_NN 79_CD ]_NN ._. However_RB this_DT approach_NN
        requires_VBZ an_DT integrated_VBN health_NN care_NN database_NN not_RB easily_RB
        applicable_JJ within_IN the_DT US_NNP health_NN care_NN model_NN ,_, and_CC the_DT
        required_JJ community_NN consent_NN is_VBZ probably_RB not_RB possible_JJ within_IN
        the_DT US_NNP legal_JJ /_NN ethical_JJ framework_NN [_NN 80_CD 81_CD ]_NN ._. Logistic_NNP
        difficulties_NNS have_VBP been_VBN mitigated_JJ by_IN the_DT steady_JJ evolution_NN in_IN
        multicentered_JJ clinical_JJ trials_NNS that_WDT has_VBZ occurred_VBN in_IN the_DT
        field_NN of_IN stroke_NN research_NN [_NN 82_CD ]_NN ._. SWISS_NNP is_VBZ designed_VBN as_IN a_DT
        multicenter_NN clinical_JJ trial_NN ,_, and_CC the_DT use_NN of_IN a_DT nationwide_JJ
        home_NN health_NN agency_NN for_IN phlebotomy_NN service_NN enables_VBZ us_PRP to_TO
        obtain_VB blood_NN from_IN siblings_NNS living_VBG far_RB away_RB from_IN one_CD
        another_DT ._. Whereas_IN a_DT requirement_NN that_IN study_NN subjects_NNS travel_VBP
        to_TO a_DT local_JJ study_NN center_NN could_MD result_VB in_IN failure_NN to_TO enroll_VB
        patients_NNS for_IN logistic_JJ reasons_NNS ,_, a_DT home_NN health_NN agency_NN can_MD
        obtain_VB blood_NN from_IN study_NN subjects_NNS rendered_VBD homebound_NN by_IN
        stroke_NN or_CC other_JJ ailments_NNS ._. Thus_RB ,_, it_PRP is_VBZ hoped_VBN that_IN this_DT study_NN
        design_NN will_MD efficiently_RB assemble_VB a_DT cohort_NN of_IN ischemic_JJ
        stroke_NN pedigrees_NNS without_IN invoking_VBG community_NN consent_NN or_CC
        using_VBG "_'' cold-calling_JJ "_'' of_IN pedigree_NN members_NNS ._.
        In_IN conclusion_NN ,_, we_PRP believe_VBP that_IN the_DT DNA_NNP samples_NNS collected_VBN
        in_IN this_DT study_NN will_MD not_RB only_RB be_VB of_IN use_NN in_IN defining_VBG regions_NNS
        of_IN the_DT genome_NN in_IN which_WDT stroke_NN genes_NNS reside_VB ._. They_PRP may_MD also_RB
        be_VB of_IN use_NN in_IN testing_NN for_IN allelic_JJ association_NN of_IN candidate_NN
        genes_NNS and_CC regions_NNS by_IN SNPs_NNP ,_, because_IN alleles_NNS that_WDT predispose_VB
        to_TO disease_NN should_MD have_VB a_DT higher_JJR allele_NN frequency_NN in_IN
        siblings_NNS who_WP share_VBP chromosomal_NN regions_NNS than_IN in_IN siblings_NNS who_WP
        do_VBP not_RB ._. Because_IN the_DT cell_NN lines_NNS are_VBP banked_JJ ,_, we_PRP hope_VBP to_TO
        facilitate_VB the_DT identification_NN of_IN stroke_NN risk_NN factor_NN genes_NNS
        both_DT directly_RB by_IN ourselves_PRP and_CC by_IN others_NNS ._.
      
      
        List_NN of_IN Abbreviations_NNP
        CADASIL_NNP ,_, cerebral_JJ autosomal_NN dominant_JJ arteriopathy_NN with_IN
        subcortical_JJ infarcts_NNS and_CC leukoencephalopathy_NN
        CEPH_NNP ,_, Centre_NNP d_SYM '_POS Etude_NNP du_NNP Polymorphisme_NNP Humain_NNP
        CHLC_NNP ,_, Cooperative_NNP Human_NNP Linkage_NNP Center_NNP
        CRF_NNP ,_, case_NN report_NN form_NN
        GDB_NNP ,_, Genome_NNP Data_NNP Base_NNP
        ICF_NNP ,_, informed_VBN consent_NN form_NN
        MLS_NNP ,_, maximum_NN likelihood_NN statistic_NN
        PIC_NNP ,_, polymorphic_JJ information_NN content_NN
        QVSFS_NNP ,_, Questionnaire_NNP for_IN Verifying_NNP Stroke-_NNP Free_NNP
        Status_NNP
        RMRF_NNP ,_, Request_NNP for_IN Medical_NNP Records_NNPS Form_NNP RR_NNP ,_, relative_JJ
        risk_NN
        SVC_NNP ,_, Stroke_NNP Verification_NNP Committee_NNP
        SWISS_NNP ,_, Siblings_NNP With_IN Ischemic_NNP Stroke_NNP Study_NNP
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
        Additional_JJ file_NN
        
        Click_NNP here_RB for_IN file_NN
      
    
  
